1. New Data on Emerging Treatments for Psoriasis

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. PASI 75 is Obsolete

6. Updates on IL-17 Targeted Therapies

7. Secukinumab OPTIMISE Phase 3b Study

8. Ixekizumab Long-Term Safety Data

9. Brodalumab Across Different Body Regions

10. IL-17 Blockers Conclusions

11. The Latest on IL-23 Targeted Treatments

12. IL-23 Blockers

13. Guselkumab Patient-Reported Outcomes From VOYAGE-2 Study

14. Tildrakizumab Patient-Reported Outcomes From reSURFACE 1 and reSURFACE 2

15. Long-Term Efficacy of Tildrakizumab

16. IL-23 Blockers Concluding Remarks

17. Targeted Agents in Development

18. Risankizumab Patient-Reported Outcomes From UltIMMa Trials

19. Mirikizumab 52-Week Efficacy Data From Phase 2 Trial

20. Mirikizumab 16-Week Data From Phase 2 Trial

21. Bimekizumab Efficacy and QoL From Phase 2 Trial

22. TYK2 A New Target in Psoriasis

23. BMS-986165 Efficacy Data From Phase 2 Trial

24. Investigational Agents Unanswered Questions

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)